Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.
about
Incidence of lymphoma in a large primary care derived cohort of cases of inflammatory polyarthritisAutoimmune/Inflammatory Arthritis Associated Lymphomas: Who Is at Risk?Incidence of malignancy in adult patients with rheumatoid arthritis: a meta-analysisEvidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in JapanNeutralizing tumor-promoting chronic inflammation: a magic bullet?What is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.Development of a health care utilisation data-based index for rheumatoid arthritis severity: a preliminary studyRisk of lymphoma and solid cancer among patients with rheumatoid arthritis in a primary care setting.Cancer risk with tumor necrosis factor alpha (TNF) inhibitors: meta-analysis of randomized controlled trials of adalimumab, etanercept, and infliximab using patient level data.Future therapeutic targets in rheumatoid arthritis?Infliximab therapy in patients with chronic sarcoidosis and pulmonary involvement.Summary of worldwide pediatric malignancies reported after exposure to etanercept.Maintenance of cytomegalovirus-specific CD4pos T-cell response in rheumatoid arthritis patients receiving anti-tumor necrosis factor treatments.Rationale of using different biological therapies in rheumatoid arthritis.A practical approach to monitoring patients on biological agents for the treatment of psoriasisMalignancy validation in a United States registry of rheumatoid arthritis patients.The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study.Ulcerative colitis: current treatment strategies and future prospects.Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended studyDo inflammatory bowel disease therapies cause cancer?Update of the management of chronic psoriasis: new approaches and emerging treatment options.Solid malignancies among etanercept-treated patients with granulomatosis with polyangiitis (Wegener's): long-term followup of a multicenter longitudinal cohort.Golimumab in patients with active rheumatoid arthritis who have previous experience with tumour necrosis factor inhibitors: results of a long-term extension of the randomised, double-blind, placebo-controlled GO-AFTER study through week 160Management of rheumatoid arthritis: consensus recommendations from the Hong Kong Society of RheumatologyThe risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials.Effects of a biologic agent in a patient with rheumatoid arthritis after treatment for methotrexate-associated B-cell lymphoma: a case report.Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists.Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonistsRisk of lymphoma in patients with RA treated with anti-TNFalpha agents.Treating rheumatic patients with a malignancy.Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and resultsSwedish registers to examine drug safety and clinical issues in RA.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort studyMalignancy risk of anti-tumor necrosis factor alpha blockers: an overview of systematic reviews and meta-analyses.Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial.Acute myeloid leukemia developing in patients with autoimmune diseases.
P2860
Q24675306-F675D9D0-68E4-4C8F-B8AC-DD141D2EAE99Q26739361-2CC59D30-189C-47BE-BE08-786002EA11C4Q26799036-FC9DECBA-8C72-4516-9A8E-071A71086540Q26829392-D2A67F57-B4AF-468D-BF85-EBB2DA7584B1Q26830931-2A300CF8-9C47-4F18-9A57-CE2D3D400B76Q28074148-407929ED-A68F-403D-9F49-915389A8F5F2Q30240212-0F2D542F-625D-4464-AA72-A9075D80C14AQ33346685-1AF0D109-ABC8-489B-A57D-4525CA50458AQ33362177-6EC1090C-B969-42AC-AE97-2DD746326625Q33734256-41843DA5-8D25-4150-AA68-60C7A37942CCQ33799604-47E00B0A-56B2-4335-B08B-A755801EEC18Q33841419-5DA9CB33-2558-4515-86C4-9EF0AE5E5DC5Q33997625-DE9B38A6-0D8F-4447-90C6-DB0950E8DAB8Q33998050-064525DA-8432-47BD-BD9B-C7A3C7672E70Q34152994-2188F7D1-C403-462E-ACA4-2071C3170EC5Q34153073-FAAB8DD4-EBAC-485B-AC18-B64719D4064AQ34156420-AD598414-C38B-4087-92C5-38C424C24EAFQ34287960-303A70CA-B016-43F3-8293-F181078AC3DAQ34363241-DDB7BD46-5EB3-425D-B8E2-D401C940083BQ34408967-DD4A2B60-CF69-4697-816C-47280D9BEAC2Q34562870-C638F90F-AA20-4297-A475-3725C4FBF993Q34613890-A01A93F5-D9A8-4CFE-AC3E-4CB3162ED952Q34620375-53AB707A-F96A-4816-B309-4D5FDED7F073Q34628409-B94D5CB7-ACB6-43EB-A574-6FFA1A05EAF3Q34637048-AE942A57-6669-422C-A67F-0A419A1C91BBQ34641300-9AFAD560-2B87-4245-B1E2-560C4949E6CCQ34984568-6039A7AD-E813-4216-9FA1-4937B57B6EA9Q35144770-62147AD8-9EB6-4622-B2B2-0DC798EA9795Q35554823-7FC3E0C4-FD4F-40AF-B0F0-B4648E709C1BQ35554865-820B6C27-3FE8-4EFC-85D1-B647F1CA4348Q35555473-0575E66E-72E3-41D1-9E1C-7205EB611B25Q35557863-09F184FF-1DC7-43D8-9097-EEAC6A7909EFQ35579517-7979012A-7AA9-4B7C-A511-2E6CB048E570Q35621627-49A768D8-89EE-4A64-8282-D08212589D0CQ35637262-85EFB936-8C59-4778-962D-6A3BBC719244Q35638252-102D6C13-0D05-4FA9-951B-E7290B5DDCDCQ35813092-1E795185-08E7-43B8-83FE-FB4F65CCE6B9Q35842876-BFFB9141-CC47-403C-AD00-22123E380E12Q35953319-894F21FA-6D47-464C-A605-3480A16CF891Q36006358-384586AB-6548-4326-835D-029A0BE140A4
P2860
Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Tumour necrosis factor blocker ...... n increased risk of lymphomas.
@ast
Tumour necrosis factor blocker ...... n increased risk of lymphomas.
@en
type
label
Tumour necrosis factor blocker ...... n increased risk of lymphomas.
@ast
Tumour necrosis factor blocker ...... n increased risk of lymphomas.
@en
prefLabel
Tumour necrosis factor blocker ...... n increased risk of lymphomas.
@ast
Tumour necrosis factor blocker ...... n increased risk of lymphomas.
@en
P2093
P2860
P356
P1476
Tumour necrosis factor blocker ...... n increased risk of lymphomas.
@en
P2093
Bladström A
Jacobsson LT
Petersson IF
Turesson C
P2860
P304
P356
10.1136/ARD.2004.030528
P407
P577
2005-02-04T00:00:00Z